Inari Medical

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in July 2011 and is headquartered in Irvine, CA.

Earnings data Q4 2020

Earnings data Q1 2020

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Inari Medical reports robust Q4 earnings and eyes international expansion

Inari Medical's Q4 2022 earnings call highlighted strong revenue growth, operational challenges, and strategic opportunities for market expansion and product innovation.
The company's focus on patient outcomes, superior product performance, and international growth positions it for continued success in 2023 and beyond.
Efforts to optimize gross margins, manage operating expenses, and drive market adoption present key areas for Inari's future financial performance and profitability.
With a clear revenue guidance for 2023 and a commitment to sustained operating profitability, Inari Medical demonstrates a strategic roadmap for sustainable growth.

Inari Medical reports robust Q1 earnings, eyes sustained profitability

Inari Medical's Q1 earnings call highlighted strong financial performance, growth strategies, and product innovations. Challenges include competitive dynamics and assessing seasonality trends. The company is well-positioned for sustained growth and market expansion.

Inari Medical reports record revenue and eyes Asian market expansion

Inari Medical's Q2 2023 performance reflects robust financial growth, international expansion, and a strategic focus on addressing unmet needs in the CVD market.
With a strong product portfolio, sustained profitability, and market development initiatives, Inari Medical is well-equipped to capitalize on growth opportunities and drive innovation.
Challenges in market entry, product redesign timelines, and regulatory approvals are being navigated as the company aims for sustained growth and market leadership in the medical device sector.

Inari Medical reports robust Q3 earnings, acquires LimFlow for growth

Inari Medical's Q3 performance reflects strong financial growth, operational improvements, and strategic acquisitions driving future prospects.
While challenges like declining margins and delayed profit targets exist, opportunities in new markets, product pricing, and synergies offer avenues for sustained growth.
The LimFlow acquisition positions Inari well in the CLTI market, with a focus on revenue growth, operational efficiency, and market expansion.
Overall, Inari's confidence in its core business and strategic moves like the LimFlow acquisition signal a positive trajectory and growth outlook.

Inari Medical reports record revenue, eyes sustained profitability amid challenges

Inari Medical's Q4 2023 performance showcased strong revenue growth, operational progress, and a strategic focus on market leadership and patient care.
While facing challenges such as regulatory scrutiny and increased operating expenses, the company remains optimistic about revenue growth and sustained profitability.
Opportunities lie in diversified revenue streams, international expansion, and product portfolio enhancements, positioning Inari for continued growth and market leadership.
Overall, Inari Medical's strategic initiatives and financial performance indicate a resilient and growth-oriented trajectory in the medical device industry.

Inari Medical reports record Q1 revenue, raises full-year guidance

Inari Medical's Q1 performance reflects robust revenue growth, strategic investments, and international expansion, positioning the company for sustained profitability and market leadership.
While facing challenges in competition and market dynamics, Inari's strengths in innovation, global performance, and product development offer avenues for growth and differentiation.
The company's focus on operational efficiency, strategic investments, and product enhancements align with opportunities in expanding toolkits, new therapies, and market presence.

Inari Medical reports record revenue, eyes sustained profitability and global expansion

Inari Medical's Q2 2024 performance reflects strong revenue growth but with operating losses, signaling a need for cost management strategies.
The company's strategic strengths lie in sustained profitability projections, successful business integrations, and expansion into key international markets.
Challenges include leadership transition risks, operational hurdles in new markets, and the need to meet high market expectations with upcoming data releases.
Opportunities for Inari include optimizing costs, leveraging growth in China and Japan, capitalizing on new product adoption, and driving further market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.

LOS ANGELES, CA / ACCESSWIRE / March 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Inari Medical, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

Inari Medical, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - NARI

NEW YORK, March 19, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inari Medical, Inc. ("Inari" or the "Company") (NASDAQ: NARI).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Inari Medical, Inc.- NARI

NEW YORK, NY / ACCESSWIRE / March 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

ATTENTION Inari Medical, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

Inari Medical (NARI) announces two-year interim results from the CLOUT registry, which shows a significant improvement in patient's post-thrombotic syndrome and lower rethrombosis-related events.

Inari Medical's (NARI) ClotTriever Improves Patient Outcome

NEW YORK, NY / ACCESSWIRE / March 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

Inari Medical, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - NARI

Rates of Post Thrombotic Syndrome at two years were excellent and significantly lower than rates reported in historical Deep Vein Thrombosis trials Rates of Post Thrombotic Syndrome at two years were excellent and significantly lower than rates reported in historical Deep Vein Thrombosis trials

Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry

NEW YORK , March 12, 2024 /PRNewswire/ -- WHY:  Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Inari Medical, Inc. (NASDAQ: NARI) resulting from allegations that Inari Medical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Inari Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NARI INVESTOR NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Inari Medical, Inc. Investors to Inquire About Securities Class Action Investigation - NARI

RADNOR, Pa. , March 12, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Inari Medical, Inc. (NASDAQ: NARI) ("Inari Medical").

Inari Medical Investigation: Kessler Topaz Meltzer & Check, LLP Investigates The Inari Medical, Inc. (NASDAQ: NARI) for Potential Securities Violations

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

NARI ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Inari Medical, Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / March 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

ATTENTION NARI SHAREHOLDERS: Investors who lost money on Inari Medical, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

Shareholders that lost money on Inari Medical, Inc.(NARI) should contact Levi & Korsinsky about Securities Fraud Investigation - NARI

NEW YORK--(BUSINESS WIRE)---- $NARI #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. (“Inari” or “the Company”) (NASDAQ: NARI). Investors who purchased Inari securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI. Investigation Details: On February 28, 2024, Inari announced its fourth quarter and full-year 2023 financial results and di.

Inari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK, NY / ACCESSWIRE / March 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

NARI ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Inari Medical, Inc.

NEW YORK, NY / ACCESSWIRE / March 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

Lost Money on Inari Medical, Inc.(NARI)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.

Reasons to Retain Inari Medical (NARI) in Your Portfolio Now

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

NARI ACTIVE INVESTIGATION: Contact Levi & Korsinsky If You Lost Money on Your Inari Medical, Inc. Investment

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

An Investigation Has Commenced on Behalf of Inari Medical, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your NARI Losses.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Inari investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws,.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Inari Medical, Inc. (NARI) on Behalf of Investors

Inari Medical, Inc. (NARI) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky, LLP Investigates

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI) investors concerning the Company's possible violations of federal securities laws. On February 28, 2024, Inari announced that it had received a civil investigative demand from the U.S. Department of Justice “in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act” requesting information.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Inari Medical, Inc. (NARI) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 28, 2024, Inari announced that it had received a civil investigative demand from the U.S. Department of Justice “in connection with an investigation under the fede.

The Law Offices of Frank R. Cruz Announces Investigation of Inari Medical, Inc. (NARI) on Behalf of Investors

Inari Medical, Inc. Being Investigated on Behalf of Inari Medical, Inc. Investors. Contact Levi & Korsinsky For Details

NEW YORK , March 2, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Inari Medical, Inc. (NASDAQ: NARI) resulting from allegations that Inari Medical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Inari Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Inari Medical, Inc. Investors to Inquire About Securities Class Action Investigation - NARI

NEW YORK--(BUSINESS WIRE)---- $NARI #ClassActionInvestigation--The law firm of Kirby McInerney LLP is investigating potential claims against Inari Medical Inc. (“Inari” or the “Company”) (NASDAQ:NARI). The investigation concerns whether Inari and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On February 28, 2024, Inari Medical released its financial results for the fourth quarter and the full year of 2023.

News for Inari Medical Stock (NARI)